ERBB2 and neoplasm: Three hundred forty-six patients were enrolled in the HER2 cohort of MyPathway with protocol-stipulated HER2 molecular alterations [reference MyPathway Protocol V4, V5] and 85 were enrolled with ERBB2-amplified and/or -overexpressing CRC based on local tumor analysis.